Ceftiofur, a third generation cephalosporin, demonstrates in vitro efficacy against microorganisms isolated from septicemic neonatal foals. This pharmacokinetic study evaluated the intravenous and subcutaneous administration of ceftiofur sodium (5mg/kg body weight; n=6 per group) and subcutaneous administration of ceftiofur crystalline free acid (6.6mg/kg body weight; n=6) in healthy foals. Plasma ceftiofur- and desfuroylceftiofur-related metabolite concentrations were measured using high performance liquid chromatography following drug administration. Mean (±SD) noncompartmental pharmacokinetic parameters for i.v. and s.c. ceftiofur sodium were: AUC 0→∝ (86.4±8.5 and 91±22h·μg/mL for i.v. and s.c., respectively), terminal elimination half-life (5.82±1.00 and 5.55±0.81h for i.v. and s.c., respectively), C max(obs) (13±1.9μg/mL s.c.), T max(obs) (0.75±0.4h for s.c.). Mean (± SD) noncompartmental pharmacokinetic parameters for s.c. ceftiofur crystalline free acid were: AUC 0→∝ (139.53±22.63h·μg/mL), terminal elimination half-life (39.7±14.7), C max(obs) (2.52±0.35μg/mL) and t max(obs) (11.33±1.63h). No adverse effects attributed to drug administration were observed in any foal. Ceftiofur- and desfuroylceftiofur-related metabolites reached sufficient plasma concentrations to effectively treat common bacterial pathogens isolated from septicemic foals.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Veterinary Pharmacology and Therapeutics|
|State||Published - Aug 2011|
ASJC Scopus subject areas